INO Therapeutics LLC

INO Therapeutics LLC, a foreign-owned subsidiary of Medtronic Inc. headquartered in Hazelwood, Missouri, supplies inhaled nitric oxide therapeutic gases, INOMAX delivery systems, and respiratory therapy services to federal healthcare agencies as a prime contractor across 586 recent awards with combined potential value of $101.2 million. The vendor operates exclusively as a prime, with no subcontractor footprint; it competes full-and-open on the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB), carrying no set-aside designations across its federal portfolio.

Customer concentration is weighted toward VA and DoD healthcare. The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 anchors the portfolio with 33 awards and $58 million in combined potential value — a decisive outlier that accounts for 57% of the vendor's total potential value. The Department of the Army Medical Command (62 awards, $11.3 million) and the Department of the Navy Bureau of Medicine and Surgery (127 awards, $5.6 million) rank second and third by dollar magnitude, though the Navy's large award count reflects many lower-value orders. The top five customers by value concentration represent 82% of combined potential value. INO Therapeutics also serves 24 additional customer agencies across VA VISNs, the Defense Health Agency, the National Institutes of Health, and military treatment facilities including Walter Reed National Military Medical Center, Naval Medical Center San Diego, and Tripler Army Medical Center.

The vendor's recent work is representative: a $324,973 delivery order from Veterans Integrated Service Network 15 for INOMAX inhaled nitric oxide with delivery system (July 2024, ultimate completion July 2026); a $512,930 delivery order from the Defense Health Agency for inhaled nitric oxide therapeutic gases and respiratory therapy services at Portsmouth, Virginia (October 2023, completion September 2028); a $417,886 definitive contract from Veterans Integrated Service Network 6 for nitric oxide gas service at VA medical centers in central Virginia (January 2023, completion December 2027); and multiple smaller delivery orders and BPA calls ranging from several hundred dollars to over $300,000 across dozens of Veterans Integrated Service Networks and military medical centers.

INO Therapeutics holds three active Blanket Purchase Agreements. The primary vehicle is a $789,408 BPA with Veterans Integrated Service Network 2 for INOMAX nitric oxide gas cylinder delivery services through September 30, 2027, awarded October 1, 2022, which has generated multiple annual option-year calls. A second $404,200 BPA with the Defense Health Agency covers inhaled nitric oxide therapeutic gas through March 19, 2030, awarded March 20, 2025. A third smaller BPA valued at $2,260 with Veterans Integrated Service Network 2 for nitrous oxide gas (inotherapy) medical supplies extends through May 31, 2027, awarded June 1, 2023. Task order activity across these three BPAs accounts for a material portion of recent awards. The vendor also places task orders directly against the GSA Pharmaceuticals and Drugs Schedule itself; 338 task orders against the schedule carry $36.3 million in combined potential value, with additional task orders against Federal Supply Schedule vehicles (V797P5726X, V797P5476X) generating $4.2 million and $21 thousand respectively.

Award activity has remained stable, with 14 awards in 2022, 13 in 2023, 14 in 2024, 15 in 2025, and 9 through September 2026 (partial year). Eighteen awards carrying combined potential value of $2.8 million face ultimate completion within the next twenty-four months and represent near-term recompete risk. Service Contract Inventory reporting shows minimal SCI-reportable service revenue: $92 thousand in FY2023 across 0.9 FTEs and $58 thousand in FY2024 across 0.3 FTEs, with zero invoiced SCI revenue in FY2025. The low SCI footprint reflects that INO Therapeutics' federal business is predominantly goods procurement (INOMAX cylinders and delivery equipment) rather than services; SCI excludes goods and products. On the small subset of contracts above the $150,000 SCI threshold where labor was invoiced, the vendor's government-paid hourly rates ran from $41.84/hr at the 10th percentile to a median of $46.62/hr, with senior labor pricing reaching $268.78/hr at the 90th percentile. The vendor self-performs all reported labor with no subcontractor engagement on SCI-reportable contracts.